Wanbury Ltd
Wanbury Q2 Results 2026 (FY27): Revenue ₹182.91 Cr, Operating margin 14.3%
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Get Wanbury Ltd's next results in your feed
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Wanbury Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores).
As stated in Wanbury Ltd's Q2 FY27 results statement · published 5 Nov 2026. Reported figures, not investment advice.
Based on Wanbury Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores). Quarterly EBITDA: ₹2,591.1 Lakhs (up 70% YoY).
From Wanbury Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Wanbury's revenue grow in the September 2026 quarter?
What happened to Wanbury's margins in Q2 FY27?
See what Wanbury Ltd said on profitability & margins — free account, 30 seconds.
What capex is Wanbury planning?
2 more points from Wanbury Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Wanbury raising money or cutting debt?
See what Wanbury Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Wanbury's order book?
See what Wanbury Ltd said on order book & pipeline — free account, 30 seconds.
Wanbury Ltd — Quarterly revenue & net profit
Wanbury Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 183 |
| Operating profit (EBITDA) | 23 |
| Operating margin | 12.4% |
| Profit before tax | 12 |
| Net profit (PAT) | 9 |
| EPS (₹) | 2.44 |
Source: Wanbury Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹183 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wanbury's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Shilpa Medicare Ltd (Q2 FY27)
2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Key investor presentation takeaways from Shilpa Medicare Ltd's Q2 FY27 investor presen
- Shukra Pharmaceuticals (Q2 FY27)
For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025. Key…
- Influx Healthtech (Q2 FY27)
Revenue from operations for H1 FY27: ₹85.4 crores . Key investor presentation takeaways from Influx Healthtech Ltd's Q2 FY27 investor presentation — and how it
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wanbury Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wanbury Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores). Quarterly EBITDA: ₹2,591.1 Lakhs (up 70% YoY).
What is Wanbury Ltd share price analysis?
Wanbury Ltd currently shows a neutral. The stock trades at a P/E of 11.3 with a market cap of ₹673 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wanbury Ltd planning capital expenditure?
The presentation states the following regarding capex, capacity expansion, and new projects:.
Keep Wanbury Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.